Marcelo De Moura Campos

Mr. Marcelo De Moura Campos

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2024 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
MCMarcelo De Moura Campos
Marcelo De Moura Campos
MCMarcelo De Moura Campos
Marcelo De Moura Campos
LBLeticia Caroline Breis
Leticia Caroline Breis
BCBeatriz Sordi Chara
Beatriz Sordi Chara
CSClara Sasse Scherer
Clara Sasse Scherer
MGMarcus Vinicius Magno Gonçalves
Marcus Vinicius Magno Gonçalves
Background Unlike cigarette smoking, environmental tobacco smoke (ETS) has not been as well described as an environmental risk for Multiple sclerosis (MS) nor as a risk factor for disease progression. Objective We systematically reviewed the association between ETS and the risk of onset and/or progression of MS. Methods We systematically screened MedLine/PubMed, Science Direct, LILACs, and SciELO searching for publications between January 1st, 2010, and July 5, 2021, with the following keywords: “multiple sclerosis and smoking”; “multiple sclerosis and passive smoking”; “multiple sclerosis and secondhand smoking”. Results Fifteen articles were included in this review, which consisted of systematic reviews with meta-analysis (N = 2), systematic reviews (N = 2), and observational studies (N = 11). Both meta-analyses reported an impact of ETS on MS onset among secondhand smokers. One of the systematic reviews selected two observational studies showing the association between ETS and MS development, and one study that did not find a significant association between ETS and the risk of MS development. The other systematic review identified selected eight articles showing a relationship between ETS and MS. Seven observational studies reported higher odds of MS onset when associated with ETS. Four observational studies did not show a relationship between ETS and MS onset or progression. Conclusion Most articles showed a positive association between ETS exposure and the risk of developing MS. On the other hand, an association between ETS and a higher risk for MS progression could not be established.

1 August 2024 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
MSMarco Antônio Machado Schlindwein
Marco Antônio Machado Schlindwein
MCMarcelo De Moura Campos
Marcelo De Moura Campos
LBLeticia Breis
Leticia Breis
BCBeatriz Sordi Chara
Beatriz Sordi Chara
CSClara Sasse Scherer
Clara Sasse Scherer
MGMarcus Vinicius Magno Gonçalves
Marcus Vinicius Magno Gonçalves
Address for correspondence: Marcelo de Moura Campos (email: marcelo.campos88@hotmail.com). Abstract Background: Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, autoimmune disorder of the central nervous system (CNS) with a prevalence of ~ 140/100 thousand inhabitants in North America and of 108/100 thousand in Europe. The etiology of MS remains unclear, but environmental and lifestyle components, accompanied by genetic susceptibility, have been associated with an increased risk of developing MS. Tobacco smoking has been consistently reported as an MS environmental risk, increasing the propensity of developing such a disorder. Moreover, smoking is additionally mentioned as a risk factor for a more aggressive disease progression. Unlike cigarette smoking, environmental tobacco smoke (ETS) has not been well described as an environmental risk for the development of MS, nor as a risk factor for disease progression. Methods: We reviewed the association between ETS and the risk of onset and/or progression of multiple sclerosis through a systematic screening of the PubMed/MEDLINE, Science Direct, LILACS, and SciELO databases in search of articles published between January 1st, 2010, and July 5th, 2021, with the following keywords: multiple sclerosis and smoking; multiple sclerosis and passive smoking; and multiple sclerosis and secondhand smoking. Results: We included 15 articles in the review, comprising 2 meta-analyses, 2 systematic reviews, and 11 observational studies. The meta-analyses reported an impact of passive smoking on the onset of MS among passive smokers. Both systematic reviews mostly reported associations between smoking and the development of MS. Seven observational studies reported higher odds of MS onset when associated with passive smoking. And four observational studies did not show a relationship between passive smoking and MS development or progression. Conclusion: Most articles showed a positive association between environmental tobacco smoke exposure and the risk of developing multiple sclerosis. On the other hand, an association between ETS and a higher risk for MS progression could not be established. Article published online: 02 October 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

18 August 2021 in Clinical and Experimental Neuroimmunology
Verified
Journal Article
Closed access
PDF file
MCMarcelo De Moura Campos
Marcelo De Moura Campos
ANAriel José Gomes Marques Neto
Ariel José Gomes Marques Neto
RKRodrigo Kleinpaul
Rodrigo Kleinpaul
MGMarcus Vinicius Magno Gonçalves
Marcus Vinicius Magno Gonçalves

9 December 2021 in Neuroimmunology Reports
Verified
Journal Article
Open access
MCMarcelo De Moura Campos
Marcelo De Moura Campos
AFAndré Eduardo De Almeida Franzoi
André Eduardo De Almeida Franzoi
MSMatheus Fellipe Nascimento De Souza
Matheus Fellipe Nascimento De Souza
GRGuilherme Zini Dos Reis
Guilherme Zini Dos Reis
DCDaniel Collares
Daniel Collares
MGMarcus Vinicius Magno Gonçalves
Marcus Vinicius Magno Gonçalves
Paraneoplastic neurological syndromes (PNS) originate from immune-mediated neuronal degeneration caused by antibodies raised against tumor cells. Symptoms are progressive and may include cochleovestibulopathy. Vestibular syndromes and neuro-otological symptoms are very common in clinical practice, but their possible paraneoplastic cause is still not well discussed. There are reports in the literature in which auditory and vestibular impairments were identified in patients with small cell lung carcinoma, thymoma, lymphoma, and renal neoplasm. Therefore, these symptoms may provide early evidence of hidden malignancies for which a timely diagnosis is crucial. The present paper discusses available reports of neuro-otological syndromes for which investigation revealed a paraneoplastic cause that, although rare, should be considered in the differential diagnosis.

1 August 2024 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
MCMarcelo De Moura Campos
Marcelo De Moura Campos
ANAriel José Gomes Marques Neto
Ariel José Gomes Marques Neto
MGMurilo Luis Geremias
Murilo Luis Geremias
MIMayra Emi Guinoza Inushi
Mayra Emi Guinoza Inushi
CHCarolina Helena Haveroth
Carolina Helena Haveroth
MGMarcus Vinicius Magno Gonçalves
Marcus Vinicius Magno Gonçalves
Address for correspondence: Marcelo de Moura Campos (email: marcelo.campos88@hotmail.com). Abstract Background: Strogyloides stercolaris is a nematode that, after infection, can remain in asymptomatic form for decades. Autoimmune neurological disorders with impairment of Th2 cell-mediated immunity or involving the use of immunosuppressive and immunomodulatory drugs might predispose patients to the hyperinfection syndrome and disseminated disease called strongyloidiasis, which is associated with a high mortality rate. Therefore, a prophylactic treatment with ivermectin has been suggested for patients from endemic regions undergoing immunosuppressive treatment. Objective: To analyze if ivermectin should be recommended in patients with autoimmune neurological disorders undergoing immunosuppressive treatment. Methods: The present is a non-systematic review. All articles used were searched in PubMed and Google Scholar. We selected the most relevant articles available in English or Portuguese. The terms used in the search were related to neuroimmunological patients, strongyloidiasis, immunosuppressive drugs, and ivermectin. Results: Ivermectin as a prophylactic treatment did not demonstrate evidence of efficacy in neurological patients with deficient cellular immunity or under an immunosuppressive therapeutic regimen. A study exposes the hypothesis that anti-parasitic medication might cause depletion of intestinal microbes that contribute to immune tolerance, which could result in a greater predisposition to neurological inflammatory disorders, such as multiple sclerosis. Current evidence indicates that ivermectin’s effectiveness is mainly limited to confirmed cases of strongyloidiasis or suspected infections, rather than as a prophylactic measure. Conclusion: Currently, there are neither studies nor evidence to assess the effectiveness and side effects of the use of ivermectin as a prophylactic treatment for strongyloidiasis in immunosuppressed neurological patients. More studies, such as clinical trials, are necessary to estimate its real effectiveness and the possible associated unwanted effects. Article published online: 02 October 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

24 October 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
MCMarcelo De Moura Campos
Marcelo De Moura Campos
EPEduardo Pagliarini
Eduardo Pagliarini
ALAmanda Locks
Amanda Locks
MGMarcus Gonçalves
Marcus Gonçalves
Lambert-Eaton myasthenic syndrome is a primary autoimmune or paraneoplastic neuromuscular disorder, which causes muscle weakness, areflexia and autonomic disorders through the production of antibodies to voltage-gated calcium channels. Diagnosis may be challenging, yet at the same time extremely important, allowing the detection of a possible underlying malignancy, in cases of paraneoplastic presentation. Some antibodies have good sensitivity and specificity for malignancy and are also discussed. Although most of times being correlated to small cell lung cancer, other types of tumors may be also found in the paraneoplastic syndrome. Misdiagnosis with Myasthenia Gravis may occur and differences between these two disorders are discussed. Therapy choice may vary from each patient depending on drug response and the situation in which the patient is encounter . Overall, the present paper brings a review of Lambert-Eaton, involving the diagnosis, as well as, the pathophysiology, differential diagnosis, tumor investigation and treatment. Also, a brief overview through guidance on therapy during the Corona Virus Disease 2019 pandemic is analyzed.